20 results
Primary objectiveThe primary objective of this study is to evaluate the efficacy of bimekizumab in subjects with moderate to severe HS.Secondary objectiveThe secondary objective of this study is to assess the safety, tolerability, immunogenicity,…
To explore the dose-response relationship between supplemental oxygen and sublingual microcirculatory perfusion and hemodynamics in healthy volunteers
Primary Study Objectives:This study tries to objectives the potential benefit of prophylactic HBOT in terms of reducing / limiting the amount of dysphagia and / or xerostomia for tumors in the head and neck, specifically originating from the…
1. To study the effect of different target PaO2's on myocardial damage, hemodynamics, microcirculation and organ perfusion in CABG patients.2. To study underlying mechanisms of hyperoxia by determining differences in oxidative stress response…
This research project aims to investigate whether hyperoxic interval training improves whole body insulin resistance, endothelial dysfunction, cardiovascular fitness, lipid metabolism and glycemic control in the treatment of deconditioned non-…
To investigate the effect of maternal hyperoxygenation with 100% in the second stage of labor and in the presence of abnormal fetal heart rate (FHR) patterns on fetal condition, instrumental delivery rate and free radical production. In case a…
1. To study the short- and long-term effect of different target PaO2's on circulatory status, organ dysfunction and outcome.2. To study underlying mechanisms of hyperoxia by determining differences in oxidative stress response between the…
To study the relation between PaO2/FiO2-ratio and FiO2
To assess the benefits and harms of two targets of partial pressure of oxygen in arterial blood (PaO2) in guiding the oxygen administration in acutely ill adults with hypoxaemic respiratory failure at ICU admission.
To assess the safety and tolerability profile of durvalumab monotherapy, durvalumab + novel oncology therapy, durvalumab + chemotherapy, anddurvalumab + novel oncology therapy + chemotherapy combinations
The purpose of this study is to find out how safe and effective a new drug called bimekizumab is for long-term use in treating hidradenitis suppurativa. Bimekizumab (hereafter referred to as *the study drug*) has been approved by the health…
The main aim is to compare the effect of a restrictive versus liberal oxygen strategy the first eight hours after trauma on the incidence of 30-day mortality and/or major respiratory complications (pneumonia and ARDS) within 30 days (combined…
In this open-label extension study, we look at how safe and effective the new medicinal product called bimekizumab (hereafter called the *study drug*) is for long-term treatment of hidradenitis suppurativa. Open label means that both you and your…
Objective(s): Primary objective:The primary objective is to demonstrate the efficacy of bimekizumab administered subcutaneously (sc) every 4 weeks (Q4W) compared to placebo in the treatment of subjects with active ankylosing spondylitis (AS).…
Primary Objective:The primary objective of this study is to compare the efficacy of bimekizumab administered scfor 16 weeks versus secukinumab at achieving complete clearance (PASI100) in subjects withmoderate to severe chronic plaque PSO.The…
Objective(s): Primary objective:The primary objective is to demonstrate the efficacy of bimekizumab administered subcutaneously every 4 weeks (sc Q4W) compared to placebo in the treatment of subjects with active nr-axSpA.Secondary objectives:The…
The primary objective of this open-label extension (OLE) study is to assess the long-term safety and tolerability of bimekizumab administered over a period of up to 112 weeks.
To assess whether HBOT reduces pain, and improves physical functioning and QoL in breast cancer patients with late radiation toxicity.
To assess clinical improvement of skin severity in patients with ichthyosis
The objective of this study is to investigate whether hyperbaric oxygen therapy twice-daily for five days (HBOT5) is superior to hyperbaric oxygen therapy once daily for ten days (HBOT10) in obtaining hearing loss recovery after AAT. This will be…